Abstract
Background The standard initial treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). In order to select patients who would benefit the most from nCRT, there is a strong need for predictive biomarkers. The aim of this study was to evaluate the role of clinical, pathological, radiological, inflammation-related genetic, and hematological parameters in the prediction of response after nCRT.
Methods In silico analysis of published transcriptomics datasets was conducted to identify the best candidate genes, whose expression will be measured using quantitative Real Time PCR (qRT-PCR) in pretreatment formaline-fixed paraffin-embedded (FFPE) samples. In this study, 75 patients with LARC, between June 2020 and January 2022, were prospectively included. Patients were assessed for tumor response in the 8th week after nCRT completion with pelvic MRI scan and rigid proctoscopy. For patients with a clinical complete response (cCR) and initially distant located tumor no immediate surgery was suggested (“watch and wait” approach). The response after surgery was assessed using histopathological tumor regression grading (TRG) categories from postoperative specimens by Mandard. Responders (R) were defined as patients with cCR without operative treatment, and those with TRG 1 and TRG 2 postoperative categories. Non-responders (NR) were patients classified as TRG 3-5.
Results Responders group comprised 35 patients (46.6%) and NR group included 53.4% of patients. Analysis of published transcriptomics data identified genes that could predict response to treatment and their significance was assessed in our cohort by qRT-PCR. When comparison was made in the subgroup of patients who were operated (TRG1 vs. TRG4), the expression of IDO1 was significantly deregulated (p<0.05). Among hematological parameters between R and NR a significant difference in the response was detected for neutrophil-to-monocyte ratio (NMR), initial basophil, eosinophil and monocyte counts (p<0.01). According to MRI findings, non-responders were more often presented with extramural vascular invasion (p<0.05).
Conclusion Based on logistic regression model, factors associated with favorable response to nCRT were found to be tumor morphology as well as hematological parameters which can be easily and routinely derived from initial laboratory results (NMR, eosinophil, basophil and monocyte counts) in a minimally invasive manner. Using various metrics, an aggregated score of the initial eosinophil, basophil, and monocyte counts demonstrated the best predictive performance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Horizon Europe Project STEPUPIORS (Agreement No. 101079217) and the Ministry of Education and Science of the Republic of Serbia (Agreement No. 451-03-47/2023-01/200043).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the Ethics Committee of the Institute for Oncology and Radiology of Serbia and the Ethics Committee of the Faculty of Medicine, University of Belgrade, Serbia. All patients signed an informed consent. All experiments have been performed in accordance with the Helsinki Declaration of 1975, as revised in 2013.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available upon reasonable request from the corresponding author. The data are not publicly available due to ethics restrictions as their containing information could compromise the privacy of patients.
List of abbreviations
- CRC
- colorectal cancer
- LARC
- locally advanced rectal cancer
- MRI
- magnetic resonance imaging
- nCRT
- neoadjuvant chemoradiotherapy
- pCR
- pathologic complete response
- cCR
- clinical complete response
- NCBI GEO
- National center for biotechnology information gene expression omnibus
- TRG
- tumor regression grading
- GSEA
- gene set enrichment analysis
- KEGG
- Kyoto encyclopedia of genes and genomes
- CT
- computed tomography
- RT
- radiotherapy
- VMAT-SIB
- volumetric modulated arc therapy-simultaneous integrated boost technique
- PR
- partial response
- FFPE
- formaline-fixed paraffin-embedded
- EDTA
- ethylenediaminetetraacetic acid
- CBC
- complete blood count
- NLR
- neutrophil-to-lymphocyte ratio
- PLR
- platelet-to-lymphocyte ratio
- dNLR
- derived neutrophil-to-lymphocyte ratio
- LMR
- lymphocyte-to-monocyte ratio
- PMR
- platelet-to-monocyte ratio
- NMR
- neutrophil-to-monocyte ratio
- UICC
- Union for International Cancer Control
- ECOG
- Eastern cooperative oncology group
- cDNA
- complementary DNA
- qRT-PCR
- quantitative Real Time PCR
- GAPDH
- glyceraldehyde-3-phosphate dehydrogenase
- SD
- standard deviation
- ROC
- receiver operating characteristics curve
- AUC ROC
- area under the ROC curve
- AUCRP
- Area Under Precision-Recall Curve
- RMSE
- Root Mean Square Error
- EMVI
- extramural vascular invasion
- RFMDA
- Random Forest Mean Decrease in Accuracy
- DFS
- disease-free survival
- anti-PD-1 inhibitor
- programmed death 1 inhibitor
- MSI
- microsatellite instability
- dMMR
- mismatch repair–deficient
